Breaking Down Tianjin Ringpu Bio-Technology Co.,Ltd. Financial Health: Key Insights for Investors

Tianjin Ringpu Bio-Technology's nine-month revenue of CNY 2,544.33 million (up 13.5% year-over-year) and TTM revenue of CNY 3.37 billion sit alongside a 2024 annual revenue of CNY 3.07 billion, while analysts project a 15.2% CAGR through 2025-yet investors should weigh that growth against profitability and balance-sheet signals: nine-month net income of CNY 362.31 million, a TTM net profit margin of 12.28%, ROE of 8.80% and operating margin of 14.33% contrast with an interest coverage ratio of -12.2 and total debt of CNY 1.4 billion (debt-to-equity 27.8%), even as cash and short-term investments total CNY 1.8 billion and liquidity ratios remain healthy (current ratio 2.08, quick ratio 1.72); valuation sits at roughly a trailing P/E near 21, P/S ≈ 2.6 and market cap around CNY 9.07 billion (EV/EBITDA ~13.37), so read on for a deep dive into where the numbers create opportunity-and where the risks lie.

Tianjin Ringpu Bio-Technology Co.,Ltd. (300119.SZ) - Revenue Analysis

Key revenue and scale metrics for Tianjin Ringpu Bio-Technology Co.,Ltd. are summarized below, highlighting recent growth trends and per-employee productivity.

• Total revenue (9 months ending Sep 30, 2025): CNY 2,544.33 million - +13.5% YoY vs CNY 2,241.62 million.
• Trailing twelve months (TTM) revenue: CNY 3.37 billion - +0.27% YoY.
• Full-year 2024 revenue: CNY 3.07 billion - +13.32% YoY from CNY 2.71 billion (previous year).
• Revenue per employee: ~CNY 1.16 million (2,900 employees).
• Market capitalization: CNY 9.07 billion; P/S ratio: 2.69.
• Analyst revenue CAGR forecast through 2025: 15.2%.

Notable operational and investment considerations:

• Revenue acceleration in 9M 2025 (+13.5% YoY) contrasts with near-flat TTM growth (+0.27%), indicating stronger recent quarterly performance skewing the year-to-date profile.
• Revenue per employee (~CNY 1.16M) provides a productivity benchmark versus peers in biotech/manufacturing.
• P/S of 2.69 vs market cap CNY 9.07B positions valuation relative to revenue growth expectations (analysts' 15.2% CAGR to 2025).

For company background and deeper context, see: Tianjin Ringpu Bio-Technology Co.,Ltd.: History, Ownership, Mission, How It Works & Makes Money

Tianjin Ringpu Bio-Technology Co.,Ltd. (300119.SZ) - Profitability Metrics

• Net income (9M ended Sep 30, 2025): CNY 362.31 million (vs. CNY 248.77 million prior-year period)
• Trailing twelve months (TTM) net profit margin: 12.28%
• Operating margin (TTM): 14.33%
• Return on equity (ROE): 8.80%
• Earnings per share (TTM EPS): CNY 0.91; Price-to-earnings (P/E): 20.93
• Analyst consensus: earnings growth ~19.1% p.a.; projected EPS for 2025: CNY 0.86

• Profitability drivers: year-over-year net income increase (~45.7% for the nine-month comparison) and robust operating margin indicate effective cost management and core-margin strength.
• Valuation context: P/E of 20.93 vs. analyst growth expectations suggests investors are paying a moderate premium for anticipated mid- to high-teens earnings growth.
• Capital efficiency: ROE at 8.80% highlights reasonable returns on equity but room for improvement relative to higher-growth peers.

Tianjin Ringpu Bio-Technology Co.,Ltd. (300119.SZ) - Debt vs. Equity Structure

Key balance-sheet and solvency metrics for Tianjin Ringpu Bio-Technology Co.,Ltd. illustrate capital composition, liquidity buffers and interest-servicing capacity:

• Total assets: CNY 7.69-7.70 billion (reported figures shown below)
• Total liabilities: CNY 2.50-2.54 billion
• Total debt: CNY 1.40 billion
• Equity base: CNY 5.20 billion
• Cash and short-term investments: CNY 1.80 billion
• Debt-to-equity ratio: 27.8%
• Interest coverage ratio (EBIT / interest): -12.2 (negative, indicating EBIT is insufficient to cover interest)

Implications for capital structure and liquidity:

• Leverage is moderate by debt-to-equity measures (27.8%) due to a sizable equity base (CNY 5.2B).
• Cash and short-term investments of CNY 1.8B create a meaningful liquidity buffer against liabilities of ~CNY 2.5B.
• Negative interest coverage (-12.2) signals operating losses or low EBIT relative to interest costs - a primary financial risk despite moderate leverage.
• The proximity of total liabilities (CNY ~2.5B) to available cash suggests operating performance, not balance-sheet solvency, is the critical near-term focus.

For context on the company's stated direction and values, see: Mission Statement, Vision, & Core Values (2026) of Tianjin Ringpu Bio-Technology Co.,Ltd.

Tianjin Ringpu Bio-Technology Co.,Ltd. (300119.SZ) - Liquidity and Solvency

• Current ratio: 2.08 - short-term assets are roughly double short-term liabilities, indicating comfortable coverage for near-term obligations.
• Quick ratio: 1.72 - excluding inventories, the company still retains strong immediate liquidity.
• Cash & short-term investments: CNY 1.8 billion - a substantial liquidity buffer relative to current liabilities.

• Debt-to-equity at 27.8% points to a conservative capital structure with limited leverage risk relative to equity.
• Total liabilities of CNY 2.5 billion against assets of CNY 7.7 billion yield a debt/assets ratio of ~32.5%, supporting balance-sheet stability.
• Negative interest coverage ratio (-12.2) signals operating losses or non-operational charges that leave earnings insufficient to cover interest - a red flag for lenders and fixed-cost resilience.

• Strong liquidity (current and quick ratios plus CNY 1.8b cash) provides runway to manage short-term obligations and fund near-term operations or R&D.
• Conservative leverage reduces refinancing and solvency risk, but profitability must improve to resolve the negative interest coverage and restore earnings-based coverage.
• Monitor earnings trends, interest expense trajectory, and any one-off items driving the negative coverage ratio; working-capital efficiency and margin recovery are key.

Tianjin Ringpu Bio-Technology Co.,Ltd. (300119.SZ) - Valuation Analysis

• Trailing P/E: 21.35 - implies investors pay CNY 21.35 for each CNY 1 of trailing net income.
• Forward P/E: 17.90 - reflects expected earnings improvement or market repricing based on analyst forecasts.
• P/S (Price-to-Sales): 2.61 - suggests the market values the company at 2.61 times annual sales.
• P/B (Price-to-Book): 1.71 - indicates the stock trades below 2x book value, near underlying net assets.
• EV/EBITDA: 13.37 - a mid-teens multiple showing the enterprise value relative to operating cash profitability.
• EV/Revenue: 2.65 - shows enterprise value is roughly 2.65 times annual revenue.
• Market Capitalization: CNY 8.75 billion; Enterprise Value: CNY 8.87 billion - small spread implies relatively low net debt or cash neutrality.

• Implication for investors: P/E compression to forward P/E 17.90 can reflect expected earnings growth, margin improvement or analyst upgrades; compare to peers and sector medians for context.
• Balance-sheet view: P/B 1.71 and narrow EV/Market Cap gap imply limited leverage - check latest debt and cash figures for confirmation.
• Relative valuation: EV/EBITDA 13.37 and EV/Revenue 2.65 place the company in a moderate valuation band; assess against biotech/chemicals peers for investment decisions.

Tianjin Ringpu Bio-Technology Co.,Ltd. (300119.SZ) Risk Factors

• Negative interest coverage: Interest coverage ratio = -12.2, indicating EBIT is insufficient to cover interest expenses and implying potential solvency pressure if operating performance does not improve.
• Leverage level: Debt-to-equity ratio = 27.8%, reflecting a relatively conservative use of debt relative to equity.
• Absolute liabilities: Total liabilities ≈ CNY 2.54 billion, which must be managed against cash flow and asset liquidity.
• Total debt burden: Total debt ≈ CNY 1.4 billion, a material obligation given current earnings weakness.
• Balance sheet size: Total assets ≈ CNY 7.69-7.7 billion, providing a coverage base for liabilities but requiring analysis of asset quality and liquidity.

• Liquidity and cash-flow risk: With negative interest coverage, operating cash flow must be monitored - recurring operating shortfalls could force asset sales or external financing.
• Refinancing and interest-rate exposure: Although leverage is modest, the absolute debt of CNY 1.4 billion requires service - adverse rate moves or tightened credit could raise financing costs or limit access to capital.
• Asset-quality and collateral risk: Total assets of ~CNY 7.7 billion provide a cushion, but the recoverable value, liquidity, and any pledged collateral should be reviewed.
• Earnings volatility: Negative EBIT relative to interest suggests earnings volatility or one-off charges; investors should analyze EBITDA trends, margins, and drivers of recent losses.
• Contingent and off-balance-sheet exposures: Given the liabilities level, contingent liabilities (guarantees, litigation) could amplify risk if present.

Tianjin Ringpu Bio-Technology Co.,Ltd. (300119.SZ) Growth Opportunities

• Analyst revenue CAGR forecast: 15.2% through 2025.
• Market capitalization: CNY 9.07 billion; Price-to-Sales (P/S): 2.69.
• Total assets: CNY 7.7 billion vs. total liabilities: CNY 2.5 billion.
• Total debt: CNY 1.4 billion; Debt-to-equity ratio: 27.8%.
• Interest coverage ratio: -12.2, signaling difficulty covering interest from operating earnings.

• Revenue expansion: 15.2% CAGR implies scalable product demand and potential market penetration gains.
• Valuation context: P/S of 2.69 and CNY 9.07 billion market cap suggest market pricing that anticipates growth but requires earnings improvement.
• Balance-sheet strength: CNY 7.7 billion in assets vs. CNY 2.5 billion liabilities provides cushion for investment and working capital.
• Leverage and liquidity risk: CNY 1.4 billion debt and negative interest coverage (-12.2) indicate near-term financing and profitability risks to monitor closely.
• Operational focus areas: improving operating margins, deleveraging, and converting forecasted revenue growth into positive EBITDA and interest coverage.